|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: ZNHIT1 |
Gene summary for ZNHIT1 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | ZNHIT1 | Gene ID | 10467 |
| Gene name | zinc finger HIT-type containing 1 | |
| Gene Alias | CG1I | |
| Cytomap | 7q22.1 | |
| Gene Type | protein-coding | GO ID | GO:0006325 | UniProtAcc | O43257 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 10467 | ZNHIT1 | Pat28-A | Human | Stomach | CSG | 8.49e-26 | 5.18e-01 | -0.2594 |
| 10467 | ZNHIT1 | Pat29-A | Human | Stomach | CAG with IM | 4.14e-21 | 6.21e-01 | -0.2769 |
| 10467 | ZNHIT1 | NAG_2 | Human | Stomach | CSG | 4.95e-02 | 2.96e-01 | -0.3324 |
| 10467 | ZNHIT1 | CAG_3 | Human | Stomach | CAG | 1.34e-06 | 2.99e-01 | -0.2766 |
| 10467 | ZNHIT1 | SIM_1 | Human | Stomach | SIM | 1.87e-03 | 2.60e-01 | 0.3573 |
| 10467 | ZNHIT1 | SIM_2 | Human | Stomach | SIM | 1.32e-11 | 3.56e-01 | 0.3139 |
| 10467 | ZNHIT1 | male-WTA | Human | Thyroid | PTC | 2.73e-60 | 3.94e-01 | 0.1037 |
| 10467 | ZNHIT1 | PTC01 | Human | Thyroid | PTC | 4.56e-13 | 5.14e-01 | 0.1899 |
| 10467 | ZNHIT1 | PTC04 | Human | Thyroid | PTC | 1.50e-06 | 4.44e-01 | 0.1927 |
| 10467 | ZNHIT1 | PTC05 | Human | Thyroid | PTC | 2.48e-28 | 1.32e+00 | 0.2065 |
| 10467 | ZNHIT1 | PTC06 | Human | Thyroid | PTC | 9.62e-48 | 1.28e+00 | 0.2057 |
| 10467 | ZNHIT1 | PTC07 | Human | Thyroid | PTC | 3.74e-80 | 1.43e+00 | 0.2044 |
| 10467 | ZNHIT1 | ATC08 | Human | Thyroid | ATC | 2.69e-15 | 3.29e-01 | 0.0541 |
| 10467 | ZNHIT1 | ATC09 | Human | Thyroid | ATC | 1.14e-13 | 5.52e-01 | 0.2871 |
| 10467 | ZNHIT1 | ATC12 | Human | Thyroid | ATC | 5.12e-16 | 7.29e-01 | 0.34 |
| 10467 | ZNHIT1 | ATC13 | Human | Thyroid | ATC | 5.82e-36 | 1.04e+00 | 0.34 |
| 10467 | ZNHIT1 | ATC1 | Human | Thyroid | ATC | 1.65e-14 | 6.45e-01 | 0.2878 |
| 10467 | ZNHIT1 | ATC2 | Human | Thyroid | ATC | 8.84e-23 | 2.29e+00 | 0.34 |
| 10467 | ZNHIT1 | ATC3 | Human | Thyroid | ATC | 1.34e-04 | -2.24e-02 | 0.338 |
| 10467 | ZNHIT1 | ATC4 | Human | Thyroid | ATC | 4.09e-33 | 1.01e+00 | 0.34 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Breast |  | IDC: Invasive ductal carcinoma |
| DCIS: Ductal carcinoma in situ | ||
| Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers | ||
| Cervix |  | CC: Cervix cancer |
| HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions | ||
| N_HPV: HPV-infected normal cervix | ||
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Endometrium |  | AEH: Atypical endometrial hyperplasia |
| EEC: Endometrioid Cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| GC |  | CAG: Chronic atrophic gastritis |
| CAG with IM: Chronic atrophic gastritis with intestinal metaplasia | ||
| CSG: Chronic superficial gastritis | ||
| GC: Gastric cancer | ||
| SIM: Severe intestinal metaplasia | ||
| WIM: Wild intestinal metaplasia | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:00063257 | Cervix | CC | chromatin organization | 78/2311 | 409/18723 | 5.40e-05 | 8.02e-04 | 78 |
| GO:00063381 | Cervix | CC | chromatin remodeling | 45/2311 | 255/18723 | 8.33e-03 | 4.30e-02 | 45 |
| GO:0006325 | Colorectum | AD | chromatin organization | 119/3918 | 409/18723 | 4.85e-05 | 8.33e-04 | 119 |
| GO:0006338 | Colorectum | AD | chromatin remodeling | 70/3918 | 255/18723 | 7.44e-03 | 4.53e-02 | 70 |
| GO:00063251 | Colorectum | SER | chromatin organization | 89/2897 | 409/18723 | 4.15e-04 | 6.17e-03 | 89 |
| GO:00063252 | Colorectum | MSS | chromatin organization | 107/3467 | 409/18723 | 7.22e-05 | 1.21e-03 | 107 |
| GO:00063258 | Endometrium | AEH | chromatin organization | 64/2100 | 409/18723 | 3.69e-03 | 2.52e-02 | 64 |
| GO:000632513 | Endometrium | EEC | chromatin organization | 65/2168 | 409/18723 | 4.98e-03 | 3.14e-02 | 65 |
| GO:000632516 | Esophagus | HGIN | chromatin organization | 92/2587 | 409/18723 | 1.05e-06 | 4.16e-05 | 92 |
| GO:000632517 | Esophagus | ESCC | chromatin organization | 240/8552 | 409/18723 | 6.52e-08 | 1.14e-06 | 240 |
| GO:0043486 | Esophagus | ESCC | histone exchange | 16/8552 | 22/18723 | 9.46e-03 | 3.28e-02 | 16 |
| GO:000632511 | Liver | HCC | chromatin organization | 206/7958 | 409/18723 | 7.23e-04 | 4.41e-03 | 206 |
| GO:000632510 | Oral cavity | OSCC | chromatin organization | 190/7305 | 409/18723 | 1.17e-03 | 5.97e-03 | 190 |
| GO:00063259 | Prostate | BPH | chromatin organization | 101/3107 | 409/18723 | 1.52e-05 | 1.94e-04 | 101 |
| GO:00063382 | Prostate | BPH | chromatin remodeling | 62/3107 | 255/18723 | 9.47e-04 | 5.97e-03 | 62 |
| GO:000632514 | Prostate | Tumor | chromatin organization | 104/3246 | 409/18723 | 2.02e-05 | 2.62e-04 | 104 |
| GO:000633811 | Prostate | Tumor | chromatin remodeling | 63/3246 | 255/18723 | 1.73e-03 | 1.02e-02 | 63 |
| GO:000632519 | Skin | cSCC | chromatin organization | 147/4864 | 409/18723 | 4.41e-06 | 6.52e-05 | 147 |
| GO:000633812 | Skin | cSCC | chromatin remodeling | 94/4864 | 255/18723 | 7.58e-05 | 7.26e-04 | 94 |
| GO:00718241 | Skin | cSCC | protein-DNA complex subunit organization | 87/4864 | 241/18723 | 3.09e-04 | 2.47e-03 | 87 |
| Page: 1 2 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| ZNHIT1 | SNV | Missense_Mutation | c.320N>A | p.Gly107Glu | p.G107E | O43257 | protein_coding | tolerated(0.18) | benign(0) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
| ZNHIT1 | SNV | Missense_Mutation | c.341N>A | p.Arg114His | p.R114H | O43257 | protein_coding | deleterious(0.03) | probably_damaging(0.998) | TCGA-AA-3672-01 | Colorectum | colon adenocarcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD | |
| ZNHIT1 | SNV | Missense_Mutation | rs764694500 | c.77G>A | p.Arg26His | p.R26H | O43257 | protein_coding | deleterious(0.04) | benign(0.001) | TCGA-A5-A0G1-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| ZNHIT1 | SNV | Missense_Mutation | rs749784309 | c.137N>T | p.Ala46Val | p.A46V | O43257 | protein_coding | deleterious(0.04) | possibly_damaging(0.569) | TCGA-A5-A0VQ-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Chemotherapy | carboplatin | SD |
| ZNHIT1 | SNV | Missense_Mutation | rs200966635 | c.80G>A | p.Arg27His | p.R27H | O43257 | protein_coding | tolerated(0.05) | benign(0) | TCGA-A5-A1OF-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| ZNHIT1 | SNV | Missense_Mutation | novel | c.434N>C | p.Gln145Pro | p.Q145P | O43257 | protein_coding | tolerated(0.09) | benign(0.092) | TCGA-AJ-A2QO-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| ZNHIT1 | SNV | Missense_Mutation | c.235N>T | p.Arg79Cys | p.R79C | O43257 | protein_coding | deleterious(0) | probably_damaging(0.991) | TCGA-AP-A0LM-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | cisplatin | SD | |
| ZNHIT1 | SNV | Missense_Mutation | c.398N>T | p.Ala133Val | p.A133V | O43257 | protein_coding | tolerated(0.06) | possibly_damaging(0.46) | TCGA-B5-A0K6-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| ZNHIT1 | SNV | Missense_Mutation | novel | c.250N>G | p.Phe84Val | p.F84V | O43257 | protein_coding | deleterious(0) | probably_damaging(0.981) | TCGA-B5-A1MR-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
| ZNHIT1 | SNV | Missense_Mutation | novel | c.49N>T | p.Arg17Trp | p.R17W | O43257 | protein_coding | deleterious(0.04) | possibly_damaging(0.876) | TCGA-D1-A103-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |